NCT04576949 - A Study of Cytisinicline for Smoking Cessation in Adult Smokers | Biotech Hunter

Enrollment

810

Participants

Timeline

Start Date

October 13, 2020

Primary Completion Date

December 23, 2021

Study Completion Date

December 23, 2021

Conditions

Smoking Cessation

Interventions

DRUG

Cytisinicline

film-coated oral tablets containing 3 mg cytisinicline

DRUG

Placebo

film-coated oral tablets containing matched placebo

BEHAVIORAL

Behavioral support

Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the subject about their attempt to quit smoking. Each session will last approximately 10 minutes.

Trial Locations (17)

14609

Rochester Clinical Research, Inc., Rochester

23502

Alliance for Multispecialty Research, LLC, Norfolk

27612

M3 Wake Research, Inc., Raleigh

29464

Coastal Carolina Research Center, Inc., Mt. Pleasant

30281

Clinical Research Atlanta, Atlanta

33134

Alliance for Multispecialty Research, LLC, Coral Gables

36608

Alliance for Multispecialty Research, LLC., Mobile

37920

Alliance for Multispecialty Research, LLC., Knoxville

40509

AMR Lexington, Lexington

47714

MediSphere Medical Research Center, LLC, Evansville

64114

Alliance for Multispecialty Research, LLC, Kansas City

67207

Alliance for Multispecialty Research, LLC, Wichita

70119

Alliance for Multispecialty Research, LLC, New Orleans

75231

FutureSearch Trials of Dallas, LP, Dallas

85044

Arizona State University, Phoenix

89119

Alliance for Multispecialty Research, LLC, Las Vegas

02114

Massachusetts General Hospital - Clinical Genetic Research Facility, Boston